2022
DOI: 10.3390/cells11071220
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive Analysis of CDK1-Associated ceRNA Network Revealing the Key Pathways LINC00460/LINC00525-Hsa-Mir-338-FAM111/ZWINT as Prognostic Biomarkers in Lung Adenocarcinoma Combined with Experiments

Abstract: Lung adenocarcinoma (LUAD) is the leading cause of cancer deaths worldwide, and effective biomarkers are still lacking for early detection and prognosis prediction. Here, based on gene expression profiles of LUAD patients from The Cancer Genome Atlas (TCGA), 806 long non-coding RNAs (lncRNAs), 122 microRNAs (miRNAs) and 1269 mRNAs associated with CDK1 were identified. The regulatory axis of LINC00460/LINC00525-hsa-mir-338-FAM111B/ZWINT was determined according to the correlation between gene expression and pat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
5
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 68 publications
1
5
0
Order By: Relevance
“…We found that six DE-lncRNAs significantly associated with the prognosis of LUAD patients, and ultimately screened out LINC00857, LINC00460, SYNPR-AS1 and RBPMS-AS1. It has been shown that LncRNA LINC00857 can regulate lung adenocarcinoma progression by targeting miR-1179/SPAG5 axis ( Wang et al, 2020 ), LINC00460 -Hsa-Mir-338-FAM111/ZWINT pathway can be used as a prognostic biomarker for lung adenocarcinoma ( Li et al, 2022 ), SYNPR-AS1 is significantly associated with overall survival of lung adenocarcinoma patients ( Wu et al, 2020 ) and the prognostic potential of RBPMS-AS1 in lung adenocarcinoma ( Wang L. et al, 2019 ), which is consistent with our findings. To assess the validity of prognostic features, we calculated patient risk scores in the TCGA training and prediction sets.…”
Section: Discussionsupporting
confidence: 91%
“…We found that six DE-lncRNAs significantly associated with the prognosis of LUAD patients, and ultimately screened out LINC00857, LINC00460, SYNPR-AS1 and RBPMS-AS1. It has been shown that LncRNA LINC00857 can regulate lung adenocarcinoma progression by targeting miR-1179/SPAG5 axis ( Wang et al, 2020 ), LINC00460 -Hsa-Mir-338-FAM111/ZWINT pathway can be used as a prognostic biomarker for lung adenocarcinoma ( Li et al, 2022 ), SYNPR-AS1 is significantly associated with overall survival of lung adenocarcinoma patients ( Wu et al, 2020 ) and the prognostic potential of RBPMS-AS1 in lung adenocarcinoma ( Wang L. et al, 2019 ), which is consistent with our findings. To assess the validity of prognostic features, we calculated patient risk scores in the TCGA training and prediction sets.…”
Section: Discussionsupporting
confidence: 91%
“…ZWINT is a crucial constituent of the mitotic spindle checkpoint, which plays a pivotal role in ensuring accurate chromosome segregation during cell division and maintaining genomic stability. [14,15] Recent studies have shown that ZWINT may be involved in the pathogenesis of tumour development and is overexpressed in a variety of malignancies including colon, breast, liver, lung and pancreatic cancers [8,[16][17][18][19][20][21] .However, the regulation of ZWINT in ovarian cancer and its molecular mechanism have not been reported yet. The results of this study showed that ZWINT was significantly highly expressed in ovarian cancer tissues, the higher the expression level of ZWINT, the worse the overall survival and disease-free survival of the patients, which indicates that ZWINT is closely related to the development of ovarian cancer.…”
Section: Discussionmentioning
confidence: 99%
“…For example, Xiang and colleagues found that FAM111B was lowly expressed in papillary thyroid cancer (PTC) tissues, leading to poor prognosis in PTC patients 4 . In addition, the over‐activation of FAM111B in pancreas, lung, cervix and breast increased the risk of related‐cancer 5–9 . Boldanova et al revealed that FAM111B was highly expressed in the tumor region of HCC patients and could be used as a biomarker for HCC patients treated with transarterial chemoembolization 10 .…”
Section: Introductionmentioning
confidence: 99%
“…4 In addition, the over-activation of FAM111B in pancreas, lung, cervix and breast increased the risk of related-cancer. [5][6][7][8][9] Boldanova et al revealed that FAM111B was highly expressed in the tumor region of HCC patients and could be used as a biomarker for HCC patients treated with transarterial chemoembolization. 10 Therefore, the course of HCC may have an inseparable relationship with FAM111B.…”
mentioning
confidence: 99%